NCT04647110

Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers.

Real-world Study of Non-small Cell Lung Cancer Treatment With ALK-tyrosine Kinase Inhibitors (ALK TKI) in Sweden: Drug Sequencing, Treatment Duration and Overall Survival - A Retrospective Study Using Swedish Register Data

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 549 (actual)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study aims to explore for the first time how the different ALK TKIs have been sequenced in real-world clinical practice and with which outcomes for Swedish lung cancer patients

Conditions

• ALK-positive NSCLC

Interventions

Type	Name	Description
DRUG	crizotinib	as provided in real world practice
DRUG	alectinib	as provided in real world practice
DRUG	brigatinib	as provided in real world practice
DRUG	ceritinib	as provided in real world practice
DRUG	lorlatinib	as provided in real world practice

Timeline

• Start date: 2020-12-14
• Primary completion: 2021-03-15
• Completion: 2021-03-15
• First posted: 2020-11-30
• Last updated: 2023-04-06
• Results posted: 2022-07-13

Locations

1 site across 1 country: Sweden

Regulatory

• FDA-regulated drug study